Latest Mergers And Acquisitions News

Terrain Minerals has raised $1.17 million through a placement to fund further drilling at its promising Smokebush Project, targeting high-grade gold and silver deposits.

ASF Group Limited reported a solid cash position of $2.44 million as of September 2025, driven by strategic investment moves and technology development, while extending its share buyback program.

Larvotto Resources has greenlit the Hillgrove Antimony-Gold Project development, securing $175 million in funding and reporting strong high-grade drilling results that bolster its resource base.

Artemis Resources has reported promising early drilling results at its Karratha Gold-Copper Project alongside key tenement grants and agreements at its Cassowary Exploration Project, supported by a recent $4.9 million capital raise.

Anagenics Limited reports a notable improvement in operating cash outflows for 1Q26, driven by cost efficiencies and strong brand performance, with Bouf Haircare on track to exceed $9 million in sales.

Great Divide Mining has poured its first gold at the Challenger Gold Mine, marking a key milestone as it moves from exploration to production. The company raised $1.335 million to support its ramp-up plans amid ongoing joint venture challenges.

Galan Lithium has completed a $20 million placement and secured Argentine government incentives, advancing its Hombre Muerto West lithium project toward first production in early 2026.

Aspire Mining Limited reports significant progress on its Ovoot Coking Coal Project, securing exclusive marketing rights and aligning infrastructure development with government-backed transport projects.

DXN Limited reports a sharp revenue decline in Q1 FY26 due to client-driven project deferrals but highlights a robust $11.9 million backlog and the imminent launch of its first Data Centre as a Service site.

West Cobar Metals reports significant progress across its WA and NSW projects, with promising assay results for rare earths and base metals, alongside strategic engagement in the US market and a recent $1.25 million capital raise.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Novatti Group has achieved positive operating cashflow and EBITDA for the September quarter, driven by strategic revenue reforms and new commercial contracts with major clients.